TBC1D5

Across TCGA pan-cancer cohorts, TBC1D5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D5 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TBC1D5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBC1D5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where TBC1D5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.257	0.501	<.001	40	view →
LUAD	DFS	Median	All	0.738	0.518	.012	18	view →
LSCC	DFS	Median	II,III,IV	0.525	0.812	.014	9	view →
HNSC	DFS	Tertile	All	0.532	0.740	.021	6	view →
CCRCC	DFS	Median	II,III,IV	0.723	0.504	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D5–GBM (DFS)

Open the GBM breakdown →